FDC Bio
- Biotech or pharma, therapeutic R&D
Seeking Global Partnerships to Bring Our Safer ADCs to the World
FDC Bio mission is to overcome toxicity barriers in ADC
- ExSAC™: A cutting-edge ADC platform with a safer TOP1i payload-linker system, 85mg/kg NHP tolerated, offering a therapeutic window that is twice as wide as conventional ADCs.
- DuPLEX™: An innovative dual payload system designed to overcome drug resistance and enhance treatment efficacy.
Pipeline Highlights:
- ADAM9-ADC: potential best-in-class ADC for gastrointestinal cancers, with an IND filing planned for Q4 2025.
- EGFR/c-MET bsADC: A dual-targeting + Dual-payload ADC aimed at combating resistance, with an IND filing scheduled for Q1 2026.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}